Cargando…
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) fai...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589680/ https://www.ncbi.nlm.nih.gov/pubmed/33004942 http://dx.doi.org/10.1038/s41409-020-01069-w |
_version_ | 1784598781764829184 |
---|---|
author | Schetelig, Johannes Chevallier, Patrice van Gelder, Michel Hoek, Jennifer Hermine, Olivier Chakraverty, Ronjon Browne, Paul Milpied, Noel Malagola, Michele Socié, Gerard Delgado, Julio Deconinck, Eric Damaj, Ghandi Maury, Sebastian Beelen, Dietrich Quoc, Stéphanie Nguyen Shankara, Paneesha Brecht, Arne Mayer, Jiri Hunault-Berger, Mathilde Bittenbring, Jörg Thieblemont, Catherine Lepretre, Stéphane Baldauf, Henning de Wreede, Liesbeth C. Tournilhac, Olivier Yakoub-Agha, Ibrahim Kröger, Nicolaus Dreger, Peter |
author_facet | Schetelig, Johannes Chevallier, Patrice van Gelder, Michel Hoek, Jennifer Hermine, Olivier Chakraverty, Ronjon Browne, Paul Milpied, Noel Malagola, Michele Socié, Gerard Delgado, Julio Deconinck, Eric Damaj, Ghandi Maury, Sebastian Beelen, Dietrich Quoc, Stéphanie Nguyen Shankara, Paneesha Brecht, Arne Mayer, Jiri Hunault-Berger, Mathilde Bittenbring, Jörg Thieblemont, Catherine Lepretre, Stéphane Baldauf, Henning de Wreede, Liesbeth C. Tournilhac, Olivier Yakoub-Agha, Ibrahim Kröger, Nicolaus Dreger, Peter |
author_sort | Schetelig, Johannes |
collection | PubMed |
description | No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53(mut/del) CLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II–IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted. |
format | Online Article Text |
id | pubmed-8589680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-85896802021-11-23 Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party Schetelig, Johannes Chevallier, Patrice van Gelder, Michel Hoek, Jennifer Hermine, Olivier Chakraverty, Ronjon Browne, Paul Milpied, Noel Malagola, Michele Socié, Gerard Delgado, Julio Deconinck, Eric Damaj, Ghandi Maury, Sebastian Beelen, Dietrich Quoc, Stéphanie Nguyen Shankara, Paneesha Brecht, Arne Mayer, Jiri Hunault-Berger, Mathilde Bittenbring, Jörg Thieblemont, Catherine Lepretre, Stéphane Baldauf, Henning de Wreede, Liesbeth C. Tournilhac, Olivier Yakoub-Agha, Ibrahim Kröger, Nicolaus Dreger, Peter Bone Marrow Transplant Article No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53(mut/del) CLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II–IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted. Nature Publishing Group UK 2020-10-02 2021 /pmc/articles/PMC8589680/ /pubmed/33004942 http://dx.doi.org/10.1038/s41409-020-01069-w Text en © The Author(s) 2020, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Schetelig, Johannes Chevallier, Patrice van Gelder, Michel Hoek, Jennifer Hermine, Olivier Chakraverty, Ronjon Browne, Paul Milpied, Noel Malagola, Michele Socié, Gerard Delgado, Julio Deconinck, Eric Damaj, Ghandi Maury, Sebastian Beelen, Dietrich Quoc, Stéphanie Nguyen Shankara, Paneesha Brecht, Arne Mayer, Jiri Hunault-Berger, Mathilde Bittenbring, Jörg Thieblemont, Catherine Lepretre, Stéphane Baldauf, Henning de Wreede, Liesbeth C. Tournilhac, Olivier Yakoub-Agha, Ibrahim Kröger, Nicolaus Dreger, Peter Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party |
title | Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party |
title_full | Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party |
title_fullStr | Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party |
title_full_unstemmed | Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party |
title_short | Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party |
title_sort | idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the ebmt chronic malignancies working party |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589680/ https://www.ncbi.nlm.nih.gov/pubmed/33004942 http://dx.doi.org/10.1038/s41409-020-01069-w |
work_keys_str_mv | AT scheteligjohannes idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT chevallierpatrice idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT vangeldermichel idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT hoekjennifer idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT hermineolivier idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT chakravertyronjon idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT brownepaul idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT milpiednoel idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT malagolamichele idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT sociegerard idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT delgadojulio idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT deconinckeric idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT damajghandi idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT maurysebastian idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT beelendietrich idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT quocstephanienguyen idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT shankarapaneesha idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT brechtarne idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT mayerjiri idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT hunaultbergermathilde idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT bittenbringjorg idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT thieblemontcatherine idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT lepretrestephane idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT baldaufhenning idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT dewreedeliesbethc idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT tournilhacolivier idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT yakoubaghaibrahim idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT krogernicolaus idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty AT dregerpeter idelalisibtreatmentpriortoallogeneicstemcelltransplantationforpatientswithchroniclymphocyticleukemiaareportfromtheebmtchronicmalignanciesworkingparty |